Table 1.
Description of participants, resected lesions, outcomes, complications, and follow-up
| Esophagus | Stomach | Colon and rectum | |
|---|---|---|---|
| Experience reported, n (%) | |||
| Their own | 51 (19) | 78 (29) | 62 (23) |
| Unit experience | 52 (11) | 76 (16) | 62 (13) |
| Number of cases treated by ESD in 2016, median (IQR) | |||
| Per endoscopist | 7 (1–21) | 6 (4–16) | 28 (5–63) |
| Per center | 10 (5–50) | 19 (8–39) | 37 (14–70) |
| Number of cases ever treated by ESD (IQR) | |||
| Per endoscopist | 25 (2–71) | 25 (11–52) | 140 (12–217) |
| Per center | 34 (15–300) | 98 (38–190) | 170 (40–340) |
| Cases scheduled for ESD in which ESD was performed, % | 92 | 90 | 82 |
| Location, % | |||
| Cardia | – | 13 | – |
| Fundus | – | 4 | – |
| Gastric body | – | 29 | – |
| Incisura | – | 19 | – |
| Antrum | – | 35 | – |
| Rectum | – | – | 44 |
| Sigmoid/descending colon | – | – | 21 |
| Transverse colon | – | – | 11 |
| Ascending colon | – | – | 25 |
| Cases >20 mm, % | 71 | 65 | 92 |
| Paris classification, % | |||
| I | 16 | 19 | 24 |
| II | 82 | 75 | 65 |
| III | 0 | 4 | 4 |
| Scar (local recurrence) | 1 | 2 | 7 |
| Histological diagnosis, % | |||
| LGIN/HGIN | 36 | 59 | |
| AC | 25 | ||
| SCC | 19 | ||
| Intramucosal carcinoma | 47 | 25 | |
| AC | 53 | ||
| SCC | 65 | ||
| Submucosal invasion | 17 | 16 | |
| AC | 22 | ||
| SCC | 16 | ||
| Short-term outcomes, % | |||
| En bloc resection | 97 | 95 | 84 |
| R0 resection | 88 | 91 | 81 |
| R1 resection | 9 | 5 | 10 |
| Rx resection | 3 | 4 | 9 |
| Curative cases | 69 | 70 | 67 |
| Complications, % | |||
| Frank perforation | 1.7 | 1.2 | 4.3 |
| Micro perforation | 1.5 | 0.8 | 2.3 |
| Major acute bleeding during procedure | 0.5 | 0.5 | 1.8 |
| Delayed bleeding | 2.8 | 4.6 | 5.2 |
| Submitted to surgery due to ESD complications | 0.5 | 0.3 | 1.7 |
| Follow-up, % | |||
| Local recurrence | 2.4 | 1.6 | 2.4 |
| Metachronous recurrence | 11.3 | 8.4 | 10.2 |
ESD, endoscopic submucosal dissection; LGIN, low grade intraepithelial neoplasia; HGIN, high grade intraepithelial neoplasia; AC, adenocarcinoma; SCC, squamous cell cancer.